CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant PatientsBusiness Wire • 02/20/25
CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic MalignanciesBusiness Wire • 02/13/25
Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect?Zacks Investment Research • 02/05/25
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?Zacks Investment Research • 01/14/25
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell TherapyPRNewsWire • 12/11/24
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell TherapyBusiness Wire • 12/11/24
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should KnowZacks Investment Research • 11/25/24
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)Zacks Investment Research • 11/15/24
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C TechnologyBusiness Wire • 10/23/24
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics MeetingBusiness Wire • 10/21/24